Menopause Review (Dec 2010)
Przydatność oceny stężenia markera CA125 w diagnostyce guzów jajnika ze szczególnym uwzglêdnieniem torbieli endometrialnych
Abstract
Background: CA125 is a mucin-derived glycoprotein. It occurs and is marked mostly among the patients withan ovarian tumour. Nowadays, CA125 antigen is considered to be the best biochemical marker for non-mucinousovarian cancers. It is also detected in pelvic inflammatory disease, endometriosis, myoma, during menstruationand the 1st trimester of pregnancy. Elevated concentrations of this marker have been also described duringnon-gynaecological conditions such as hepatocirrhosis and liver cancer, pancreatic, lung, stomach cancers, aswell as in lymphoma. Objectives: The aim of the study was to evaluate diagnostic accuracy of CA125 concentration as a markerfor ovarian tumours with special consideration of ovarian endometriotic cysts. Material and methods: A total of 124 women with ovarian tumours were included in the study. Patientswere divided into three groups: 1. with malignant neoplasm of epithelial origin (n = 30); 2. with ovarian endometrioticcysts (n = 31); 3. with benign ovarian tumours other than endometriotic (n = 63).Prior to planned surgery, CA125 serum level has been estimated in each case. Results: There were statistically significant differences in mean concentration of CA125 between patientswith an ovarian cancer and patients with benign ovarian tumours other than endometriotic (p < 0.001). Similarly,statistically significant differences occurred between patients with ovarian endometriotic cysts and patientswith non-endometriotic, benign ovarian tumours (p < 0.001). A statistically significant difference has been alsoobserved between patients with endometriotic cysts and patients with an ovarian cancer. Conclusions: 1. Elevated CA125 levels were observed in epithelial neoplasms and also in endometriotic tumours.2. Elevated CA125 levels were not observed in non-endometriotic benign ovarian tumours. 3. Low CA125concentrations can occur in both endometriotic cysts and epithelial malignant ovarian tumours.
